Table 2 Factors investigated for association with 30-day case fatality (univariate analysis)

Male

42/283 (15%)

18/175(10%)

1.44 (0.86-2.42)

0.20

*Age-adjusted Charlson > median (4)

48/230 (21%)

12/228 (5.3%)

3.97 (2.16-7.26)

<0.001

Source of bacteremia

0.001

  Unknown

26/224 (12%)

  Urinary

6/88 (6.8%)

  Biliary

4/63 (6.3%)

  Bowel

7/33 (21.1%)

  Pneumonia

12/30 (40%)

  Skin and soft tissue infection

3/11 (28%)

  Bone and joint

2/7 (29%)

  CNS

0/1 (0%)

  CVS

0/1 (0%)

Location of acquisition

0.015

  Nosocomial

41/232 (17.7%)

  Healthcare associated

11/129 (8.5%)

  Community-acquired

8/97 (8.2%)

Microbiology**

0.012

Enterobacter spp.

33/255 (13%)

  E. aerogenes

5/34 (15%)

  E. asburiae

0/1 (0%)

  E. cancerogenus

0/2 (0%)

  E. cloacae

26/210 (13%)

  E. sakazakii

2/6 (33%)

  E. spp.

0/2 (0%)

Serratia spp.

18/73 (25%)

  S. liquefaciens

2/3 (66%)

  S. marcescens

15/67 (22%)

  S. odorfera

1/1 (100%)

  S. spp.

0/2 (0%)

Citrobacter spp.**

1/51 (2.0%)

  C. braakii

0/17 (0%)

  C. freundii

1/30 (3.3%)

  C. spp.

0/2 (0%)

  C. youngae

0/2 (0%)

Escherichia coli

1/30 (3.3%)

Morganella morganii

4/27 (15%)

Providencia spp.

2/12 (17%)

  P. rettgeri

1/3 (33%)

  P. stuartii

1/9 (11%)

Hafnei alvei

1/7 (14%)

Salmonella spp.

0/2 (0%)

Klebsiella pneumoniae

0/1 (0%)

Plasmid mediated

1/33 (3.0%)

59/425 (14%)

0.22(0.03-1.53)

0.10

Description of empiric therapy

0.12

Empiric therapy in hours at:

  t = 0

23/172 (13%)

  t > 0 and t = 8

11/105 (10%)

  t >8 and t = 24

17/114 (15%)

  t > 24 and t = 48

3/36 (8.3%)

  Empiric at t > 48 hrs.

3/26 (12%)

  Never received empiric therapy.

3/5 (60%)

Description of adequate therapy

0.05

Adequate therapy in hours at:

  t = 0 hrs.

11/98 (11%)

  t > 0 and t = 8

11/96 (11%)

  t >8 and t = 24

23/133 (17%)

  t > 24 and t = 48

5/62 (8.1%)

  t > 48 hrs.

4/52 (7.7%)

  Never received adequate or definitive therapy.

6/17 (35%)